Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-Current Assets (2021 - 2025)

Lyra Therapeutics has reported Non-Current Assets over the past 5 years, most recently at $19.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $19.8 million for Q4 2025, down 14.94% from a year ago — trailing twelve months through Dec 2025 was $84.4 million (down 32.37% YoY), and the annual figure for FY2025 was $19.8 million, down 14.94%.
  • Non-Current Assets for Q4 2025 was $19.8 million at Lyra Therapeutics, down from $20.7 million in the prior quarter.
  • Over the last five years, Non-Current Assets for LYRA hit a ceiling of $52.1 million in Q1 2024 and a floor of $5.6 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $12.4 million (2022), compared with a mean of $16.8 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 474.31% in 2024 and later tumbled 56.97% in 2025.
  • Lyra Therapeutics' Non-Current Assets stood at $6.9 million in 2021, then skyrocketed by 31.52% to $9.1 million in 2022, then soared by 313.38% to $37.8 million in 2023, then crashed by 38.27% to $23.3 million in 2024, then decreased by 14.94% to $19.8 million in 2025.
  • The last three reported values for Non-Current Assets were $19.8 million (Q4 2025), $20.7 million (Q3 2025), and $21.5 million (Q2 2025) per Business Quant data.